Pulmonx Corporation (LUNG) Market Cap
Pulmonx Corporation has a market capitalization of $54.9M.
Financials based on reported quarter end 2025-12-31
Price: $1.30
▼ -0.03 (-2.26%)
Market Cap: 54.91M
NASDAQ · time unavailable
CEO: Glendon E. French
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2020-10-01
Website: https://pulmonx.com
Pulmonx Corporation (LUNG) - Company Information
Market Cap: 54.91M · Sector: Healthcare
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Analyst Sentiment
Based on 9 ratings
Analyst 1Y Forecast: $3.25
Average target (based on 3 sources)
Consensus Price Target
Low
$4
Median
$4
High
$4
Average
$4
Potential Upside: 207.7%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
Management’s tone is “rebuild and execute,” emphasizing a disciplined cost reset (over 10% ongoing opex reduction) and a near-to-far U.S. sales strategy centered on Zephyr Valves physician champions and COPD education. They attribute 2025 U.S. weakness to specific operational failures—too many competing initiatives, disruptive Territory Manager changes, and a 2025 incentive/quota allocation construct that contributed to large turnover (directionally ~half the U.S. sales org across 2025). However, the Q&A pressure shows the stock needs earlier traction than a ramp narrative: even with “nearly all” openings filled, management still guided a back-half 2026 U.S. growth resumption and described productivity ramp as typically 6–9 months. Financially, Q4 gross margin improved by ~360 bps YoY (77.6%), but U.S. revenue fell 11% YoY in Q4 and cash declined to $69.8M. Near-term hurdles remain (China distributor sales still minimal in 1H 2026), so execution—not promises—will be the catalyst.
Growth Catalysts
- AeriSeal CONVERT II pivotal trial enrollment momentum accelerating (enrollment completion expected in 2027; aimed to expand global TAM by ~20%)
- Zephyr Valves clinical performance and physician champions as the strongest program driver
- Sales focus re-directed to COPD + patient education within closest treating hospital systems
Business Development
- Pulmonx added 10 new U.S. treating centers during Q4 2025
- China distributor underperformance due to lack of sales while awaiting renewal of Chinese registration certificate (expected in 2H 2026)
Financial Highlights
- Q4 2025 total revenue: $22.6M vs $23.8M prior year (-5% YoY; -7% constant currency)
- Q4 2025 U.S. revenue: $14.1M vs $15.9M (-11% YoY)
- FY 2025 total revenue: $90.5M (+8% YoY; +7% constant currency)
- FY 2025 U.S. revenue: $57M (+1% YoY)
- Q4 2025 international revenue: $8.5M vs $7.9M (+8% YoY; +2% constant currency)
- FY 2025 international revenue: $33.5M (+23% YoY; +19% constant currency)
- Gross margin Q4 2025: 77.6% vs 74.0% (+360 bps YoY), driven by lower mix of distributor sales
- Gross margin FY 2025: 74.0%
- Net loss Q4 2025: $10.4M (-$0.25/share) vs $13.2M (-$0.33/share) prior year; FY 2025 net loss: $54M (-$1.33/share)
- Cost actions: operating expenses Q4 2025 decreased 11% YoY; FY 2025 operating expenses increased 1% YoY (3% ex-SBC)
- Cash runway: cash/cash equivalents/marketable securities ended $69.8M (down $31.7M vs 12/31/2024)
Capital Funding
- Debt refinancing: $60M credit facility, 5-year interest-only structure
- Initial $40M term loan drawn at closing (refinances prior debt); option to draw additional $20M through end of 2027 subject to revenue milestones
- Annual cash burn reduction target: $32M in 2025 to $23M in 2026 (nearly 30% reduction)
Strategy & Ops
- Cost restructuring: reduced ongoing operating expenses by over 10%
- Sales org execution issues in 2025 attributed to: (1) too many competing initiatives, (2) disruptive change to U.S. Territory Manager roles/responsibilities at start of 2025, (3) suboptimal 2025 U.S. sales incentive structure
- Sales turnover (hard estimate given): directionally on the order of ~half the U.S. sales organization across 2025; not concentrated in Q4
- Sales team strategy streamlining: move to a small set of high-impact U.S. mandates; near-to-far approach focusing first on treating physicians
- Operational horizon for ramp: new reps/territories typically require ~6-9 months to reach productivity curve
- Lower-return activity refocus: LungTraX Detect not shelved; focused on certain hospital subsets where all elements are in place
Market Outlook
- FY 2026 revenue guidance: $90M to $92M
- Gross margin FY 2026: ~75% (slightly higher in 1H; lower in 2H as distributor sales mix increases)
- FY 2026 operating expense guidance: $113M to $115M inclusive of ~$21M noncash SBC
- OpEx ex-SBC: implied 7% to 9% decrease vs 2025
- U.S. sales growth expected to resume in back half of 2026 (gradual ramp from mid- to high single-digit YoY declines in 1Q toward high single-digit growth in Q4)
- International: 1H 2026 growth negatively impacted by minimal China distributor sales; international growth expected to resume in 2H 2026
Risks & Headwinds
- U.S. revenue underperformance in 2025 largely internal/executional: sales org stretched across untested initiatives; disruptive territory manager role changes; incentive plan/quota allocation created difficulty meeting expected earnings; resulted in large turnover (~half the organization across the year)
- Q4/IH softness expected partially due to ramp time from newly filled territories and different sales force average tenure
- International headwind: lack of sales to China distributor while awaiting renewal of Chinese registration certificate (anticipated in 2H 2026), causing 1H 2026 revenue pressure
- Gross margin sensitivity: 2026 gross margin expected to decline in 2H due to increased distributor sales mix
Sentiment: MIXED
Note: This summary was synthesized by AI from the LUNG Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.